Global Opthalmic Drugs Market By Overview
Ophthalmic Drugs Market was valued at US$ 39.5 Billion in 2024 and is projected to grow at a CAGR of 4.70% to reach US$ 60.2 Billion by 2034.
Ophthalmic drug is that the administration of a drug to the eyes, most typically as an eye fixed drop formulation. Topical formulations are wont to combat a mess of diseased states of the attention. These states may include bacterial infections, eye injury, glaucoma, and dry eye. However, there are many challenges related to topical delivery of medicine to the cornea of the attention. The most important factor that has got to be taken under consideration when designing any sort of drug delivery device, and specifically ocular devices, is that the release rate of a drug. As discussed previously, the deliver rate and kinetics related to drugs to the attention can reach levels that are toxic to the attention or could even cause undesirable side effects. The speed of release of a drug is additionally important because too slow of a release could haven't any beneficial outcome for the patient and a release that's too quick could end in negative side effects. Thus, it's important to balance the factors that govern the discharge of medicine from contact lenses as potential drug delivery devices. Ophthalmic
Global Opthalmic Drugs Market By Dynamics
Increasing Prevalence of Eye Related Disorder
Increasing incidence and prevalence of eye related disorders like presbyopia, degeneration, and diabetic retinopathy among the aging population. With the introduction of Ophthalmic devices equipped with sophisticated technologies, people are increasingly choosing ophthalmic surgeries to correct their eye related disorders.
Lack of Insurance
Lack of insurance amongst population especially within the developing countries or lack of insurance covering all kinds of IOLs or contact in developed countries may be a significant challenge faced by the ophthalmology industry. The opposite challenges include low awareness about the ophthalmic disorders, especially in developing countries. This is often primarily thanks to the shortage of awareness amongst rural population about the varied ophthalmic disorders like cataract.
Global Opthalmic Drugs Market By Segmentation
Ophthalmic Drugs Market report segments the market on the basis of Disease Indication, Therapeutic Class, Distribution Channel and Region.
On the basis of Disease Indication, Ophthalmic Drugs Market is segmented into Dry Eye, Glaucoma, and Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others).
On the basis of Therapeutic Class, the target market is segmented into Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others).
On Basis of Distribution Channel, the global market is classified into Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores.
Regional Insights:
For detailed understanding of market dynamics, based on region Ophthalmic Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in North America region is seen to have a matured growth since this market correlates with the increasing growth rate of eye disease. In North America region is the dominating region due to the U.S. is the largest share of market holder of the ophthalmic drugs. In U.S., FDA gives approval to the specific indication, tax credits for drugs.
|
Attribute |
Details |
|
Base year for estimation |
2023 |
|
Forecast period |
2024 – 2034 |
|
Market representation |
Revenue in USD Million & CAGR from 2024 – 2034 |
|
Market Segmentation |
By Disease Indication - Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others
By Therapeutic Class - Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others
By Distribution Channel - Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Ophthalmic Drugs Market, By Disease Indication:
- Dry Eye
- Glaucoma
- Infection/Inflammation
- Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy)
- Others
Ophthalmic Drugs Market, By Therapeutic Class:
- Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids)
- Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others)
- Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others)
- Anti-allergy Drugs
- Anti-VEGF Agents
- Others
Ophthalmic Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies
- Drug Stores
Ophthalmic Drugs Market, By Region:
- North America
- Middle East & Africa
- Middle East & Africa Ophthalmic Drugs Market, By Disease Indication
- Middle East & Africa Ophthalmic Drugs Market, By Therapeutic Class
- Middle East & Africa Ophthalmic Drugs Market, By Distribution Channel
- Middle East & Africa Ophthalmic Drugs Market, By Country
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Latin America Ophthalmic Drugs Market, By Disease Indication
- Latin America Ophthalmic Drugs Market, By Therapeutic Class
- Latin America Ophthalmic Drugs Market, By Distribution Channel
- Latin America Ophthalmic Drugs Market, By Country
- Brazil
- Mexico
- Rest of Latin America
- Asia Pacific
- Asia Pacific Ophthalmic Drugs Market, By Disease Indication
- Asia Pacific Ophthalmic Drugs Market, By Therapeutic Class
- Asia Pacific Ophthalmic Drugs Market, By Distribution Channel
- Asia Pacific Ophthalmic Drugs Market, By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Europe
- Europe Ophthalmic Drugs Market, By Disease Indication
- Europe Ophthalmic Drugs Market, By Therapeutic Class
- Europe Ophthalmic Drugs Market, By Distribution Channel
- Asia Pacific Ophthalmic Drugs Market, By Country
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- North America Ophthalmic Drugs Market, By Disease Indication
- North America Ophthalmic Drugs Market, By Therapeutic Class
- North America Ophthalmic Drugs Market, By Distribution Channel
- Asia Pacific Ophthalmic Drugs Market, By Country
- U.S.
- Canada
- Middle East & Africa
Global Opthalmic Drugs Market By Key Players
Key players in Ophthalmic Drugs Market includes, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis AG), Genentech, Inc., Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc. and Pfizer Inc.
Global Opthalmic Drugs Market By Company Profile
- Santen Pharmaceutical Co., Ltd.
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Bausch & Lomb Inc.
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Shire Plc
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Alcon (Novartis AG)
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Genentech, Inc.
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Allergan, Plc
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- sun Pharmaceutical Industries Limited
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Actavis Generics (Teva Pharmaceutical Industries Ltd.)
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
- Pfizer Inc.
- Company Overview
- Disease Indication Portfolio
- Key Highlights
- Financial Performance
Global Opthalmic Drugs Market By Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Ophthalmic Drugs Strategies
- Key Questions this Study will Answer
- Market Snippet, By Disease Indication
- Market Snippet, By Therapeutic Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Disease Indication, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Dry Eye
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Glaucoma
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Infection/Inflammation
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Retinol Disorder
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By Therapeutic Class, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Anti-Inflammatory Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Anti-Infective Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Anti-Glaucoma Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Anti-Allergy Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Anti-VEGF Agents
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Market Segmentation, By Distribution Channel, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Online Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Independent Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Drug Stores
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
- Overview
- Global Market, By Region, 2024 – 2034, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
- Y-o-Y Growth Analysis (%), 2024 – 2034
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Disease Indication, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Therapeutic Class, Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Disease Indication, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Therapeutic Class, Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Disease Indication, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Therapeutic Class, Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Disease Indication, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Therapeutic Class, Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Disease Indication, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Therapeutic Class, Type, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Distribution Channel, 2024 – 2034
- Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- AbbVie Inc.
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Key Highlights
- Celgene Corporation
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Key Highlights
- Biogen
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Key Highlights
- Teva Pharmaceutical Industries
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
- F. Hoffmann-La Roche AG
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
- Bristol-Myers Squibb Company
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
- Alexion Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
- Amgen
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
- Merck & Co. Inc.
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
- Jazz Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Key Highlights
- Financial Performance
The Last Word
- Future Impact
- About Us
- Contact
FAQs
The opthalmic drugs market report segments the market on the basis of disease indication, therapeutic class, distribution channel, and region.
Increasing incidence and prevalence of eye related disorders like presbyopia, degeneration, and diabetic retinopathy among the aging population.
North America region is seen to have a matured growth since this market correlates with the increasing growth rate of eye disease.
Key players in the opthalmic drugs market includes, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis AG), Genentech, Inc., Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.